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Background: Testicular germ cell tumors (TGCTs) account for 1-2% of all tumors in young and middle aged men.
A 75-fold increase in TCGT development has been reported for monozygotic (MZ) twins. Therefore, the occurrence
of simultaneous tumors in MZ twins emphasizes the importance of genetic factors that influence the risk of developing
these tumors. Genomic screening was performed for one family containing MZ twins with testicular germ cell tumors,
in order to define alterations associated with risk of tumor development.
Methods: Copy number alterations were evaluated using array-CGH (4x44K, Agilent Technologies) in one seminoma
and one embryonal carcinoma (EC) from MZ twins. In addition, genomic alterations from the tumors and peripheral
blood cells of the twins were compared to the parental genomes via their peripheral blood cells.
Results: Embryonal carcinoma (Twin-1 t) presented a lower frequency of genomic alterations compared to the
seminoma (Twin-2 t). One minimal common region of loss was observed in 9p13.1-p12 in the comparison between
DNA from blood samples for Twin-1 and Twin-2. In this region is mapped the CNTNAP3 gene which was confirmed as
involved in losses by qPCR. Comparative analysis of novel CNVs between the Twin-1 t and Twin-2 t showed five
minimal common regions involving gain at chromosomes 12 (12p12.3-p11.1 and 12p13.33-p12.3), while losses
were observed at 10p15.3-p15.2, 13q21.1-q21.2 and 15q11.1-q11.2. In addition, one exclusive rare copy number
alteration was detected in Twin-1 t and Twin-2 t, and 19 novel alterations were identified in the Twin-2 t.
Conclusion: Distinct genomic profiles for MZ twins with phenotypically different TGCT were described. Of
particular interest, 12p gains were detected exclusively in tumor samples. In peripheral blood samples, loss of
9p13.1-p12 was the unique novel CNV shared by the twins, confirming the involvement of CNTNAP3 gene in
TGCTs development. Although similar CNV profiles were shared by both the peripheral blood and tumor samples of
the twins, tumor-specific CNV loci were identified for seminoma and non-seminomatous tumors. These findings
suggest the presence of de novo germline structural alterations and TGCT predisposition.
Keywords: Testicular germ cell tumors, Seminomas, Embryonal carcinoma, Array-based comparative genomic
hybridization, Molecular markers, Genomic imbalances, Copy number variationsBackground
Testicular tumors are relatively uncommon, accounting
for 1-2% of all tumors in males. Testicular germ cell tumors
(TGCTs) represent 95% of testicular cancers and are
histologically classified as seminoma or non-seminoma
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unless otherwise stated.that resembles primordial germ cells (PGCs) [2]. Non-
seminomatous tumors are classified as embryonic (tera-
toma) and extra-embryonic (yolk sac and choriocarcinoma)
according to their pattern of cell differentiation, or as
embryonal cell carcinomas when originating from un-
differentiated cells [3,4]. It is important to highlight that
non-seminomatous mixed germ cell tumors display a more
aggressive clinical behavior, frequently developing local
recurrence and distant metastasis [5].
The presence of these tumors in monozygotic (MZ)
twins is extremely rare and therefore, it is difficult toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Monozygotic and dizygotic twins present a 75 and 35-fold
increased risk of developing TCGT, respectively [6]. In a
meta-analysis of testicular cancer in twins, two of seven
studies demonstrated a significantly increased risk of
testicular cancer among twins [7]. Therefore, a simultan-
eous occurrence of tumors in MZ twins stresses the
importance of a genetic factor, which influences their risk
of development.
The etiology of testicular cancer is not completely under-
stood, however, a number of risk factors have been de-
scribed in the literature, including cryptorchidism, a family
history of testicular cancer, testicular atrophy, testicular
microlithiasis, infertility, HIV infection and imbalance
of estrogen and androgen levels in twin pregnancies
[8-11]. In addition, rare inherited diseases, such as Down’s
syndrome, Klinefelter’s syndrome, and XY dysgenesis, are
associated with an increased risk for testicular cancer [12].
Gains at Xq27, XRCC1 polymorphisms and deletions of
the Y chromosome have been described as associated with
susceptibility to testicular germ cell tumor [13-17]. Recent
genome-wide association studies (GWAS) have identified
29 SNPs mapped at 18 TGCT predisposition loci [18-22].
Several genes have been described as associated with
TGCT susceptibility including TERT, SPRY4, BAK1,
DMRT1, ATF7IP and KITLG.
In the present study, a genomic screening approach
was performed for a pair of 26-year old male MZ twins
with embryonal carcinoma and testicular seminoma. Copy
number variations (CNV) analyses were presented and
discussed with reference to the parental genome, which
allowed for the assessment of genomic alterations and
respective harbored genes involved in the development
of the testicular germ cell tumors.Figure 1 Identical twins diagnosed with different subtypes of testicular
detail, showing a papillary growth pattern. C) Seminoma nodule within the teMethods
Case description
A pair of male MZ twins with a diagnosis of TGCTs was
admitted to the Sarcoma’s Nucleus of the A. C. Camargo
Cancer Center, São Paulo, Brazil. Array-CGH analysis was
successfully performed for the primary tumors (embryonal
carcinoma and seminoma) and the peripheral blood
samples from the twins and their parents. Neither pa-
tient had received chemotherapy or radiotherapy prior
to sample collection. Furthermore, neither twin presented
risk factors associated with TCGT as described in the lit-
erature (cryptorchidism, familial testicular cancer history,
testicular atrophy, testicular microlithiasis, infertility, HIV
infection and alterations of estrogen and androgen levels
during pregnancy). All family members were advised of
the procedures and provided written informed consent.
The Human Research Ethics Committee of the Institution
approved the study (Protocol EC 21/2014).
Twin-1 was submitted to a right orchiectomy after pre-
senting with a palpable tumor in the right testicle at 21 years
of age. Histopathological analysis revealed a mixed germ
cell tumor (pT2NxMx) containing both embryonal car-
cinoma (95%) and mature teratoma (5%) components
(Figure 1A-B). Immunohistochemistry for the embryonal
carcinoma was positive for CD30 and negative for PLAP,
HCG and alpha- fetoprotein. Despite the presence of
lymphatic and venous invasion, the adjacent testicular
anatomy (tunica albuginea and vaginalis) was not compro-
mised and no invasion of the spermatic cord was observed.
The surgical margins were negative for the presence of
tumor cells. Due to the presence of pulmonary metastases,
the patient underwent a three-day regimen of adjuvant
chemotherapy with bleomycin, etoposide and cisplatin
(BEP), with a complete response. Three years after thegerm cell tumors. A) Embryonal carcinoma. B) Embryonal carcinoma in
stis D) Seminoma in detail, showing large round cells with lymphocytes.
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testicle. Histopathological evaluation revealed a mature
teratoma, clinical stage IA. Subsequently, the patient had a
left orchiectomy and after 6 years of follow-up remains
disease-free.
Twin-2 was submitted to a right orchiectomy at 22 years
of age, after presenting with a palpable tumor in the
right testicle. Histopathological analyses revealed a pure
classical seminoma (pT1NxMx) (Figure 1C-D) with no
vascular or lymphatic invasion. The adjacent testicular
anatomy (rete testis, epididymis, tunica albuginea, tunica
vaginalis and spermatic cord) was not compromised. It was
pathologically staged as 1A, indicated a good prognosis;
therefore no adjuvant treatment was required. Fifteen
months later, testicular ultrasound detected a new solid
nodule in the left testicle measuring 0.5 cm, associated
with microlithiasis, diagnosed as a classic seminoma, with-
out any other germ cell component. The patient underwent
wedge resection of the tumor nodule and adjuvant radio-
therapy (25.5 Gy) was administered to the remaining testis.
After four years of follow-up, the patient remains disease-
free.
Genome screening using array-based comparative genomic
hybridization (array- CGH)
Formalin fixed paraffin-embedded tumors, one embryonal
carcinoma (Twin-1 t) and one seminoma (Twin-2 t), were
macro-dissected and genomic DNA extracted using a
standard phenol/chloroform method. The same protocol
was applied for DNA extraction from peripheral blood
from the twins and their parents. The Peripheral blood
samples, tumors and reference genomic DNA (Promega,
G1471, male) were differentially labeled using a Genomic
DNA Enzymatic Labeling Kit (Agilent Technologies, Santa
Clara, CA, USA). Hybridization was performed using
Agilent Human CGH 44 K Oligo Microarrays according
to the manufacturer’s instructions. The array images
were acquired using a DNA microarray scanner with
Surescan High- Resolution Technology (Agilent Tech-
nologies, Santa Clara, CA) and Scan Control (version 8.1,
Agilent Technologies) software. The data were extracted
and normalized using the Feature Extraction software
(version 10.1.1.1, Agilent Technologies). Statistical analysis
was performed using the Nexus Copy Number software
(version 7.5 – Hg19, Biodiscovery Inc., El Segundo, CA,
USA). The Fast Adaptive States Segmentation Tech-
nique 2 (FASST2) algorithm and Significance Testing for
Aberrant Copy number (STAC) statistical methods were
used to identify non-random genomic copy-number
alterations [23]. According to these algorithms, DNA
copy number alteration was defined as follows: exceeding
the significance threshold of 1×10−5; containing at least
three consecutive altered probes per segment; and speci-
fied 1000 kb as being the maximum spacing betweenadjacent probes. These parameters were used to define the
values for copy number gains (log2 ≥ 0.2), high copy num-
ber gains (log2 ≥ 0.6), losses (log2 ≤ −0.2) and homozygous
losses (log2 ≤ −1.0).
Copy number variation analyses
The altered genomic regions observed were initially com-
pared with the CNV described in the Database of Genomic
Variants (DGV) (http://dgvbeta.tcag.ca/dgv/app/home?
ref=GRCh37/hg19/, November 2013) and then with a
CNV reference obtained from a database of the Brazilian
population [24]. The CNVs were subsequently classified ac-
cording to their genomic size and polymorphic frequency
as follows: common (regions larger than 100 kb and often
present in DGV frequencies greater than or equal to 1%);
rare (regions larger than 100 kb and often present in DGV
frequencies less than or equal to 1%); and novel (regions
larger than 100 kb and not yet described in the DGV). This
study focused only on rare or novel CNVs. Despite the ma-
jority of the CNV described in this study having a partial
intersection with the common regions identified in the
DGV database, the total CNV length had not yet been
described in either the DGV or the Brazilian database.
In addition, only genes mapped in these regions not
covered by common CNVs were considered.
Quantitative real-time PCR (qPCR) analysis
The genomic DNA sequences of candidate region were
obtained from the Ensembl Genome Browser website
(GRCh37/hg19 Human Reference Assembly; February 2009).
The reactions were performed in triplicate and followed
PCR cycling conditions as previously described by [25].
Briefly, primer pair of CNTNAP3 gene (covering the same
probes represented in the 4x44K Agilent plataform)
was designed to amplify the altered regions detected by
using array-CGH (Forward: TCCAGACAGATGAGCA
AAACATA; Reverse: AGAAAGAAAGACAACTCTCTGC
T). Delta-delta Ct model was used to calculated the rela-
tive copy numbers [26] based on the CNTNAP3/HPRT
(reference gene) ratio. This value was defined as a loss
when the ratio was <0.68 and as a gain when the ratio
was >1.47.
Results and discussion
There is a strong hereditary component in testicular germ
cell tumors as demonstrated by twin studies [6,7,27,28].
Over the past 10 years, pertinent advances have been
reported in MZ twin CNV studies, revealing an association
with disease susceptibility, including neurological disor-
ders (amyotrophic lateral sclerosis, Parkinson disease and
Lewy body dementia) and psychiatric disorders (autism,
bipolar disorder and schizophrenia) [29-32]. The present
study is thought to be the first report demonstrating the
novel and rare CNV profiles of a pair of MZ twins with
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design was used for both the peripheral blood samples
from the twins and their parents as well as the tumors
(seminoma and embryonal carcinoma) from twins.
Comparison between constitutional CNVs from parents
and siblings
The array-CGH profiles obtained from the genomic
DNA of the peripheral blood from the father (Parent-1)
and the mother (Parent-2) were compared to their sons
(Twin-1b and Twin-2b). Parents and siblings shared
similar patterns in terms of common CNVs. Rare or
novel CNVs were not detected during these compari-
sons, most likely due to the low resolution of the plat-
form. The peripheral blood samples from the MZ twins
presented a discordant genotype profile, suggesting the
contribution of post- zygotic events. The differences in
genetic profiles of MZ twins has been previously charac-
terized according to alterations involving the number or
morphology of chromosomes, chromosomal mosaicism,
single nucleotide polymorphisms and epigenetic modifi-
cations [33]. In this study, a panel of potentially patho-
genic and novel CNVs was identified by array-CGH in
each twin (Tables 1 and 2).
Comparison between the genomic profiles of the blood
and tumor from Twin-1
The comparison between the genomic alterations found
in the peripheral blood and tumor samples from Twin-1Table 1 Significant copy number variation (CNVs) regions det
Cytoband# Samples Start Stop Length
(pb)Blood Tumor
9p12-p13.1 Twin-1b 38.944.256 40.498.819 1554563
Twin-2b
10p15.3-p15.2 Twin-1 t 1,056,859 3,168,906 2112047
Twin-2 t
12p12.3-p11.1 Twin-1 t 15.161.204 34.278.525 19117321
Twin-2 t
12p13.33- p12.3 Twin-1 t 0 14.900.955 14900955
Twin-2 t
13q21.1-q21.2 Twin-1 t 58.321.428 60.493.818 2172390
Twin-2 t
15q11.1-q11.2 Twin-1 t 20.335.887 23.044.681 2708794
Twin-2 t
Xq27.3 Twin-2b Twin-2 t 144.344.622 145.204.327 859.706
Xq28 Twin-1b Twin-1 t 150.522.209 153.914.671 3.392.463
Legend: #: It was found only novel CNVs in the blood and tumor samples from monoz
this representative chromosome region. The complete gene list is deposited in G
Accession number: GSE62779.revealed the presence of minimal regions of gain at
Xq28. The Xq28 locus harbored seven genes (MAGEA2,
MAGEA2B, FATE1, LAGE3, CTAG1B, CTAG1A and
CTAG2), three of which are responsible for encoding the
cancer-testis antigens CTAG1B, CTAG1A and CTAG2.
The cancer-testis antigens (CTA) are highly expressed in
normal germ line cells as well as in many cancers, where
they are associated with advanced disease and a poor
prognosis [34,35]. Several studies have demonstrated
that CTA production in tumor cells occurs due to reacti-
vation of the gametogenic expression program as result
of genomic instability [35-37]. In the present study, gains
of Xq28 CTA-cluster in embryonal carcinoma and blood
samples obtained from Twin-1 were identified. This
cluster was not observed for the seminomatous from
Twin-2.
Comparison between the genomic profile in blood and
tumor from Twin-2
The peripheral blood and tumor samples from Twin-2
shared novel CNV involving gains at Xq27.3. This CNV
was not detected in embryonal carcinoma from Twin-1.
Nine genes were mapped on Xq27.3, including six miR-
NAs (miR890, miR888, miR891A, miR891B, miR892A
and miR892B). miR890 and miR888 have previously
been described as body fluid-specific, only detected in
semen and epididymal tissue [38]. However, no associ-
ation has been described for TGCT. Although these
findings are interesting, further studies are required inected by array-CGH
Event N° Gene ID
Loss 7 CNTNAP3, SPATA31A1, SPATA31A2, ZNF658B,
LOC653501, DQ586551 and CNTNAP3B
Loss 18 ADARB2, ADARB2-AS1, AK097474, AK127347,
AX748285, IDI1, IDI2, IDI2-AS1, PFKP, WDR37*
Gain 126 PLCZ1, CAPZA3, CASC1, KRAS, ASUN, PPFIBP1,
DDX11, MANSC4, KLHL42, PTHLH*
Gain 351 ACRBP, AKAP3, CCND2, DDX47, LRP6, NANOG, YBX3,
CACNA1C, FGF6, FKBP4*
Loss 6 AK097816, BC032915, CR618830, DIAPH3, TDRD3 and DIAP3
Loss 140 SNORD116I, SNORD115, SNORD107, SNORD64,
MAGEL2, NDN, SNURF, PAR-SN, PAR5, SNORD108*
Gain 9 SLITRK2, TMEM257, MIR892C, MIR890, MIR888,
MIR892A, MIR892B, MIR891B and MIR891A
Gain 7 MAGEA2, MAGEA2B, FATE1, LAGE3, CTAG1B,
CTAG1A and CTAG2
ygotic twins (DGV and Brazilian Database). *More than 10 genes were mapped in
ene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/).
Table 2 Specific rare and novel CNVs detected in embryonal carcinoma (Twin-1t) and seminoma (Twin-2t)
Tumor Sample Cytoband Start (pb) Stop (pb) Size (pb) Event CNV Classificationa Genesb
Twin-1 t 16p11.2-p11.1 34.059.589 34.847.384 787796 Gain R NI
Twin-2 t 1p31.1 77.762.182 78.226.565 464384 Gain N NI
1p22.1 93.075.850 93.586.348 510499 Gain N NI
2p23.3 27.431.951 27.496.511 64561 Gain N EIF2B4
2q33.1 201.865.021 202.014.428 149408 Gain N NI
3q13.13 110.529.591 110.874.657 345067 Loss N NI
3q13.33 120.713.729 120.813.244 99516 Gain N NI
6p21.1 42.257.603 42.545.298 287696 Gain N GUCA1A,GUCA1B, MRPS10 and TRERF1
8p11.23 39.003.502 39.157.973 154472 Loss N ADAM9 and ADAM32
10q24.1-q24.2 99.386.286 99.516.551 130266 Gain N PI4K2A, AVPI1, MARVELD1, ZFYVE27 and SFRP5
12q13.3-q14.1 56.296.387 56.308.803 12417 Loss N NI
12q24.31 119.381.319 119.652.493 271175 Gain N NI
14q11.2 20.550.697 20.622.417 71721 Loss N NI
14q23.1 58.887.110 59.149.379 262270 Loss N NI
15q25.3-q26.1 86.730.625 86.986.408 255784 Gain N MRPL46, MRPS11, DET1, MIR1179, MIR7-2,
MIR3529, AEN and ISG20
17p11.2 19.968.313 20.108.133 139821 Loss N NI
17p13.1 7.423.749 7.459.204 35456 Gain N NI
19q13.43 62.712.083 62.882.866 170784 Gain N ZNF773, ZNF549, ZNF550, ZNF416, ZIK1,
ZNF530, ZNF134, ZNF211 and ZSCAN4
20q11.21 29.352.138 29.447.677 95540 Gain N DEFB116, DEFB118 and DEFB119
Xp22.12-p22.11 20.043.034 21.803.101 1760068 Gain R SCARNA9L, SMPX, YY2 and MBTPS2
Legend: CNV – copy number variation; Twin-1 t – embryonal carcinoma; Twin-2 t – seminoma. Rare – R; Novel – N; No identified – NI. a - CNV classification based
on the Database of Genomic Variants and in the Brazilian population reference database. b- Genes mapped in regions described as rare or novel CNV.
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miRNAs are associated with risk of developing TGCT.
Comparison between the peripheral blood samples from
Twin-1 and Twin-2
Although 9p12-p13.1 losses were covered by common
CNVs, the region remained included for analysis due to
its presence in blood of Twin-1 and Twin-2 (Figure 2).
In addition, this region harbors potential candidate
genes that have been previously described in TGCT.
Seven genes were mapped in this region, including two
members of the SPATA31 (AEP1) subfamily (SPATA31A1
and SPATA31A2) and CNTNAP3. The SPATA31 testis-
specific gene codified an integral component of membrane
that has been associated to spermatogenesis and the cell
differentiation process, possibly playing a role in acrosome
formation [39,40]. CNTNAP3 gene encodes a protein
associated to cell-recognition process within the nervous
system [41]. Although no significant by the criteria used in
our study, loss of CNTNAP3 was detected by array-CGH
in both tumor samples from twins (two consecutive
probes). Quantitative real-time PCR (qPCR) was per-
formed to confirm the loss at 9p13.1-p12 involving the
CNTNAP3 gene. Relative DNA copy number loss wasfound in both, blood and tumor (homozygous deletion)
from twins (Figure 2). The controls and parental blood
samples showed relative DNA copy number within the
reference interval. The qPCR analysis confirmed the
array-CGH results as well as the homozygous deletions
found in tumor samples. Overall, these data suggest that
the genes mapped on 9p12-13.1 have a strong potential to
be involved in testicular tumor development.
Panel of novel CNVs shared by seminoma and embryonial
carcinoma
The presence of rare or novel CNVs detected in seminoma
and embryonal carcinoma suggests a common mechanism
that contributes to tumorigenesis. Comparative analysis of
novel CNVs from the embryonal carcinoma and semi-
noma revealed five minimal common regions, involving
gain at chromosome 12 (12p12.3-p11.1 and 12p13.33-
p12.3), while losses were observed at 10p15.3-p15.2,
13q21.1-q21.2 and 15q11.1-q11.2 (Figure 3).
DNA copy number alterations involving 12p have been
described in both seminoma and non-seminoma. Ampli-
fication of 12p, as observed in the tumor samples from
Twin-1 and Twin2 (Additional file 1), was first described
by Atkin et al. [42], and subsequently in other studies
Figure 2 (See legend on next page.)
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Figure 2 Array-CGH profile showing loss at 9p13.1-p12 was confirmed by qPCR for CNTNAP3 gene. (A-B) 9p13.1-p12 loss was the unique
novel CNV shared by the Twin-1 (A) and Twin-2 (B). Scatter plots with x-axis coordinate representing the probes positions along the genome.
The low bars (red) indicate losses of genomic regions. The images were adapted from the Nexus 7.5 software. (C) Relative quantification of
CNTNAP3 copy number alterations evaluated by qPCR. Normal DNA copy number (two copies) was found in the controls and parental blood.
Losses were found in peripheral blood and tumor cells from twins. Image obtained from Graphpad Prism 5 (Graphpad Software Inc., La Jolla, CA).
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cells responsible for determining intratubular germ cell
neoplasia of the unclassified type, suggesting that posses-
sion of this alteration contributes to an invasive pheno-
type [47-49]. Several candidate target genes have been
mapped to this region, including KRAS and CCND2,
which have been associated with the malignant transform-
ation process via the activation of pathways involved in cell
proliferation [48,50], or in the maintenance of germ cell
pluripotency, such as DPPA3 and NANOG [46,51]. Further-
more, we identified several spermatogenesis-associated
genes mapped in 12p12.3-p11.1 and 12p13.33-p12.3 includ-
ing ACRBP, AKAP3, DDX47, PLCZ1, CAPZA3, ASUN and
DDX11.
Eighteen genes mapped at deleted region 10p15.3-p15.2
including PFKP, ADARB2 and WDR37. In agreement withFigure 3 Schematic representation of the genomic alterations
detected in peripheral blood cells (b) and tumors (t) from the
parents and twins. In peripheral blood, loss of 9p13.1-p12 was the
unique novel CNV shared by the twins. Two specific CNVs mapped
in chromosome X were shared by both tumor and blood samples of
each sibling, including Xq28 for Twin-1 and Xq27.3 for Twin-2. The
panel of novel CNVs shared by embryonal carcinoma (Twin-1 t) and
the seminoma (Twin-2 t), including gains at 12p (12p12.3-p11.1 and
12p13.33-p12.3), as well as losses at 10p15.3-p15.2, 13q21.1-q21.2
and 15q11.1-q11.2. None of these novel CNVs were shared with the
parental genotypes.our findings, Hofer et al. [52] reported PFKP down-
expression among 55 differently expressed genes in semi-
nomas and embryonal carcinomas. A high incidence of
13q deletion has been reported in primary TGCTs
[43,44,53] and in non-seminomatous germ cell tumours
with acquired treatment resistance [53]. In our study, it
was detected losses of 13q21.1-q21.2, which harbors seven
genes, including DIAPH3, TDRD3 and DIAP3. Loss of
15q11.1-q11.2 was also observed for both tumors, and
involved the SNORD small nucleolar RNA (snoRNA) clus-
ter. The SNORD116I and SNORD115 genes belong to the
C/D box family of snoRNAs, and present a number of im-
portant regulatory RNA editing functions. Further studies
are necessary to clarify the involvement of these small
RNAs on the development of TGCT.
Panel of the rare and novel tumor-specific CNVs
The comparative analysis of seminoma and embryonal
carcinoma obtained from MZ twins revealed a panel of
two rare and 19 novel tumor-specific CNVs (Table 2).
To our knowledge, four studies evaluated copy number
variations in TGCT [54-57]. Using array-CGH, Edsgärd
et al. [54] analyzed the profile of pathologic CNVs in
families with germ cell tumors, including TGCT. How-
ever, only common variants were identified, including
heterozygous deletion involving RLN1 (9p24.1). Subse-
quently the authors had evaluated common and rare
CNVs in a TGCC case–control cohort, but no single
locus was found to be associated with these tumors.
Instead, the authors described one potential deletion of
PTPN1 gene (mapped at 20q13) as rare CNVs [55].
Stadler et al. [56] described three de novo CNV events
involving amplification of 7q11.22 and 12q24.1, and loss
of 6p21.2 in 3/43 familial testicular germ cell tumor trios
evaluated. In a cohort of 212 cases of TGCT and 437
controls, Dalgaard et al. [57] reported a weak association
for rare CNV in relation to cell migration in TGCT.
These altered-locus or genes were not detected in our
analysis. In agreement to the previous studies, our data
suggest an association between several de novo germline
structural aberrations and TGCT predisposition rather
than one rare event influencing the phenotype.
Conclusion
This study constitutes the first report describing rare
and novel CNVs of TGCT in monozygotic twins with
divergent genomic profiles. Several CNV regions that
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TGCT pathogenesis. Loss of CNTNAP3 mapped at
9p13.1-p12 was confirmed as involved in TGCT devel-
opment. Of particular importance, a pathognomonic
gain of 12p was confirmed exclusively in tumor samples,
which was not observed in the peripheral blood of the
twins or their parents. Although similar CNV profiles
were shared by for both the peripheral blood and tumor
samples of the twins, tumor-specific CNV loci were
identified for seminoma and non- seminomatous tumors,
which suggest a CNV origin for de novo events.Availability of supporting data
The data set supporting the results of this article is avail-
able in the Gene Expression Omnibus (GEO) repository
(www.ncbi.nlm.nih.gov/geo/). Accession number: GSE62779.Additional file
Additional file 1: Figure S1. Hybridization profile for 12p amplification
identified in tumor samples of twins. In embryonal carcinoma (A-B) and the
seminoma (C), gains at 12p were important novel CNV mapped at 12p
amplicon. The 12p12.3-p11.1 (A) and 12p13.33-p12.3 (B) were detected in
Twin-1 and 12p13.33-p11.1 (C) amplicon was detected in Twin-2. Scatter
plots with x-axis coordinate representing the probes positions along the
genome. The top bars (blue) indicate gains of genomic regions, whereas
the lower bars (red) indicate losses of genomic regions. The images were
adapted from the Nexus 7.5 software.
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